AACE Clinical Case Reports最新文献

{"title":"Occult Metastatic Papillary Thyroid Cancer in an Adolescent","authors":"Anna Chin MD, MPH ,&nbsp;Renee Robilliard DO ,&nbsp;Jan C. Groblewski MD ,&nbsp;John M. Tarro MD ,&nbsp;Sonja Chen MD ,&nbsp;Lisa Swartz Topor MD, MMSc","doi":"10.1016/j.aace.2023.11.005","DOIUrl":"10.1016/j.aace.2023.11.005","url":null,"abstract":"<div><h3>Background/Objective</h3><p>Occult papillary thyroid carcinoma (PTC) is PTC with metastasis but without identification of primary thyroid cancer on preoperative ultrasonography. Published reports on occult PTC in children are limited.</p></div><div><h3>Case Report</h3><p>We describe a 16-year-old female with occult PTC who initially presented with a painless left sided cystic neck mass. Diffuse sclerosing variant papillary thyroid cancer was found in the resected neck mass and thyroid ultrasound did not show any nodules or features of carcinoma. After total thyroidectomy, pathological examination of the thyroid revealed papillary thyroid microcarcinoma.</p></div><div><h3>Discussion</h3><p>We describe a rare case of occult diffuse sclerosing variant papillary thyroid cancer presenting as a cystic neck mass mimicking a second branchial cleft cyst in an adolescent patient. When metastatic PTC is found without evidence of nodule on thyroid imaging, occult PTC of the thyroid is the likely diagnosis.</p></div><div><h3>Conclusion</h3><p>Total thyroidectomy ± neck dissection followed by TSH suppression and radioactive iodine therapy remains the appropriate diagnostic and therapeutic interventions.</p></div>","PeriodicalId":7051,"journal":{"name":"AACE Clinical Case Reports","volume":"10 1","pages":"Pages 27-30"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S237606052300161X/pdfft?md5=f627d61413e2612caba140941d4df0dc&pid=1-s2.0-S237606052300161X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139292778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prolactinoma and Adenomyosis – More than Meets the Eye: A Case Report","authors":"Shereen Khattab BSc, MSc, MD Candidate ,&nbsp;Catherine H. Yu MD, MHSc, FRCPC ,&nbsp;Sapna Shah MD, FRCPC","doi":"10.1016/j.aace.2023.11.002","DOIUrl":"10.1016/j.aace.2023.11.002","url":null,"abstract":"<div><h3>Background/Objective</h3><p>To report a case of adenomyosis in a woman with hyperprolactinemia which resolved after initiation of dopamine agonist therapy.</p></div><div><h3>Case Report</h3><p>A 35-year-old woman with a history of Graves’ disease was referred for evaluation of hyperthyroidism in March 2020. She was started on methimazole and thyroid function normalized. The patient also had a history of a pituitary microadenoma and was previously treated with cabergoline which was stopped after 12 months as she became pregnant.</p><p>In July 2020, the patient began to have polymenorrhea. Hyperprolactinemia was thought to be an unlikely cause as it most often causes hypogonadotropic hypogonadism with amenorrhea. A pelvic ultrasound demonstrated a bulky uterus with adenomyosis. Gynecology recommended treating adenomyosis by lowering her prolactin levels. She was started on cabergoline 0.25 mg weekly in October 2021. Within 2 months of initiation of cabergoline, she had resolution of symptoms and radiological resolution of adenomyosis.</p></div><div><h3>Discussion</h3><p>Prolactin has been implicated in the pathogenesis of adenomyosis, endometriosis and leiomyomas suggesting that a decrease in prolactin levels may suppress these lesions. The pathogenesis of adenomyosis has been related to direct prolactin effects in the promotion of gland/cell proliferation and function.</p></div><div><h3>Conclusion</h3><p>We conclude that prolonged elevation in prolactin may result in the development of adenomyosis and subsequent prolonged abnormal uterine bleeding. Dopamine agonists, like cabergoline, inhibit the synthesis and secretion of prolactin from the pituitary gland and may have a role in the management of adenomyosis in patients with hyperprolactinemia.</p></div>","PeriodicalId":7051,"journal":{"name":"AACE Clinical Case Reports","volume":"10 1","pages":"Pages 20-23"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S237606052300158X/pdfft?md5=ad583d516928fff5f04d9ac98d52800c&pid=1-s2.0-S237606052300158X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135716939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Right Hand Must Know What the Left Hand is Doing: A False-Positive Hotspot on the Sestamibi Scan","authors":"Zahid Sundas MD ,&nbsp;Han Dao MD ,&nbsp;Smita Kumar MD ,&nbsp;Alan A. Thomay MD ,&nbsp;Adnan Haider MD","doi":"10.1016/j.aace.2023.11.001","DOIUrl":"10.1016/j.aace.2023.11.001","url":null,"abstract":"<div><h3>Objective</h3><p>Imaging studies in the setting of primary hyperparathyroidism are performed to rule out an ectopic parathyroid adenoma. Although rare, false-positive scans can cause confusion and possibly more extensive procedures.</p></div><div><h3>Method</h3><p>A 68-year-old woman with parathyroid hormone–dependent hypercalcemia was found to have uptake in the left midclavicular area on the parathyroid scan with sestamibi. Retention of the isotope was considered a possibility, and the sestamibi scan was repeated after injecting the isotope in the right hand and this did not show uptake in the left midclavicular area.</p></div><div><h3>Results</h3><p>Sestamibi is taken up by the mitochondrial-rich adenoma cells and can help identify an ectopic location of the adenoma. Sestamibi scans are commonly performed before neck exploration to rule out an ectopic adenoma and to localize the parathyroid adenoma. Thyroid adenoma and thyroid cancer can also cause retention of isotopes. Retention of the isotope in the vein can also give an illusion of an ectopic parathyroid adenoma. Injecting the isotope in the contralateral hand can overcome this retention issue.</p></div><div><h3>Conclusion</h3><p>Uptake on parathyroid scan outside of normal embryologic decent of the parathyroid gland should raise the possibility of a false-positive uptake.</p></div>","PeriodicalId":7051,"journal":{"name":"AACE Clinical Case Reports","volume":"10 1","pages":"Pages 17-19"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2376060523001578/pdfft?md5=10d665b825c6ae3fa023e73110811865&pid=1-s2.0-S2376060523001578-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135411459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pituitary Abscess Causing Panhypopituitarism in a Patient With Neurobrucellosis: Case Report","authors":"Gustavo De la Peña-Sosa MD,&nbsp;Abraham I. Cabello-Hernández MD,&nbsp;Roxana P. Gómez-Ruíz MD,&nbsp;Miguel A. Gómez-Sámano MD,&nbsp;Francisco J. Gómez-Pérez MD","doi":"10.1016/j.aace.2023.10.005","DOIUrl":"10.1016/j.aace.2023.10.005","url":null,"abstract":"<div><h3>Background/Objective</h3><p>Pituitary abscess is an uncommon life-threatening disease that could lead to panhypopituitarism. It is important to suspect its prevalence in regions with endemic infectious diseases.</p></div><div><h3>Case Report</h3><p>A 55-year-old man, a farmer, with a background of consumption of unpasteurized dairy products, presented with headache, impaired consciousness, and fever that started in February 2023. Initial test results were consistent with neuroinfection. Brain MRI showed ventriculitis; the pituitary gland was heterogeneous with the presence of an 8 × 8 mm abscess. The pituitary hormone axis was evaluated, and it showed results compatible with the results of panhypopituitarism with central hypothyroidism, central hypocortisolism, central hypogonadism, and growth hormone deficiency. Hormone replacement treatment with hydrocortisone and levothyroxine was started. The Rose Bengal test for <em>Brucella spp.</em> and 2-mercaptoethanol Brucella agglutination test showed positive results. After neurobrucellosis (NB) was diagnosed, antibiotic treatment was commenced. The patient was discharged 6 weeks later and treatment with prednisone, levothyroxine, recombinant somatropin, testosterone, as well as doxycycline, and rifampin was continued for another 4 months.</p></div><div><h3>Discussion</h3><p>NB and pituitary abscess are rare manifestations of brucellosis and are challenging to diagnose due to their nonspecific clinical presentation and cerebrospinal fluid (CSF) findings. NB diagnosis relies on neurologic symptoms and serological evidence of Brucella infection. Magnetic resonance imaging is the preferred diagnostic tool for pituitary abscesses. Medical management may be sufficient, while transsphenoidal drainage is not always necessary. Hormonal deficits typically remain permanent.</p></div><div><h3>Conclusion</h3><p>Pituitary abscess could be suspected in patients presenting with symptoms of neuroinfection, panhypopituitarism, and heterogenous image in the magnetic resonance imaging differential diagnosis. Opportune management can lead to reduced mortality and improved recovery of the pituitary hormone function.</p></div>","PeriodicalId":7051,"journal":{"name":"AACE Clinical Case Reports","volume":"10 1","pages":"Pages 10-13"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2376060523001463/pdfft?md5=3d6abb2eba4ddf58e48a008d5a498277&pid=1-s2.0-S2376060523001463-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136152797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Paraganglioma of the Recurrent Laryngeal Nerve","authors":"Thomas Dougherty MD ,&nbsp;Gabriela Aitken MD ,&nbsp;Richard Mack Harrell MD ,&nbsp;Courtney Edwards MD ,&nbsp;Sol V. Guerrero MD ,&nbsp;David Bimston MD","doi":"10.1016/j.aace.2023.07.002","DOIUrl":"10.1016/j.aace.2023.07.002","url":null,"abstract":"<div><h3>Background/Objective</h3><p>Paragangliomas are rare neuroendocrine tumors that primarily arise in the adrenal gland. Head and neck paragangliomas comprise approximately 3% of all extra-adrenal paragangliomas, with a majority of those being found in the carotid body. Recurrent laryngeal nerve paragangliomas are exceedingly rare, with only 2 reported cases found in literature review. Here, we will present the third.</p></div><div><h3>Case Report</h3><p>The patient is a 46-year-old woman with a history of a right thyroid nodule that had been previously biopsied benign with “paucity of diagnostic material.” Neck ultrasonography revealed a 7.4 cm nodule that demonstrated interval growth over a 2-year period, so it was recommended to proceed with right thyroid lobectomy and isthmusectomy. During resection, the recurrent laryngeal nerve appeared to “disappear” into the nodule, and it was resected along with the nodule to ensure proper margins. The nerve was reconstructed with an ansa cervicalis interposition graft, and the nodule was sent to pathology. Pathology revealed that the nodule was a 4.8 cm paraganglioma of the recurrent laryngeal nerve.</p></div><div><h3>Discussion</h3><p>Paragangliomas of the head and neck are exceedingly rare. In patients who present with symptoms of dysphagia or dysphonia, further workup, including laryngoscopy and magnetic resonance imaging, could potentially identify and allow for appropriate planning for surgical resection.</p></div><div><h3>Conclusion</h3><p>In rare cases, consideration of paraganglioma as part of the differential for thyroid nodules may assist with planning of surgery but will unlikely alter treatment.</p></div>","PeriodicalId":7051,"journal":{"name":"AACE Clinical Case Reports","volume":"10 1","pages":"Pages 24-26"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S237606052300127X/pdfft?md5=1a78cd27805705381c09a866481fd0a8&pid=1-s2.0-S237606052300127X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41987837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Osteoporosis Improved by Romosozumab Therapy in a Patient With Type I Osteogenesis Imperfecta","authors":"Antara Dattagupta MD, MEng ,&nbsp;Steven Petak MD, JD","doi":"10.1016/j.aace.2023.10.002","DOIUrl":"10.1016/j.aace.2023.10.002","url":null,"abstract":"<div><h3>Background/Objective</h3><p>Osteogenesis imperfecta (OI) is a genetic disorder that affects type 1 collagen synthesis causing increased bone fragility, low bone mass, and skeletal deformity. Bisphosphonates are recommended for treatment of OI patients; however, the efficacy of sclerostin inhibitors such as romosozumab has not been determined in OI patients with osteoporosis.</p></div><div><h3>Case Report</h3><p>A 52-year-old G2P2 clinically diagnosed with OI, with a history of multiple fractures beginning in childhood presented with low bone mass. On physical examination, blue sclera was observed. She was previously treated with alendronate therapy from April 2014 to June 2015 without significant improvement in bone mineral density (BMD). After the onset of menopause, she began romosozumab 210 mg subcutaneous therapy once a month for 12 months. Repeat dual-energy X-ray absorptiometry showed an increase of 10.3% in BMD of the spine and a 5.4% increase in BMD of the right hip. The trabecular bone score increased by 5.2%.</p></div><div><h3>Discussion</h3><p>Current literature is limited regarding the use of sclerostin inhibitors in OI patients. Our patient’s improvement in BMD of the spine and right hip after romosozumab therapy was significant at a 95% confidence level, compared to treatment initiation. Her trabecular bone score also improved significantly. Six months into our patient’s treatment course, a case in Japan of a male with severe osteoporotic OI and recurrent fractures showed improvement in BMD after romosozumab therapy.</p></div><div><h3>Conclusion</h3><p>This case highlights our patient’s significant response to romosozumab and warrants further investigation of romosozumab as a potential treatment option for OI patients with osteoporosis.</p></div>","PeriodicalId":7051,"journal":{"name":"AACE Clinical Case Reports","volume":"9 6","pages":"Pages 209-212"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2376060523001438/pdfft?md5=bba0031cf23791a62fc02128f68a37a0&pid=1-s2.0-S2376060523001438-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136094713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Encephalopathy of Autoimmune Origin: Steroid-Responsive Encephalopathy With Associated Thyroiditis","authors":"Bharadwaj Adithya-Sateesh MS ,&nbsp;Nicole Gousy MS ,&nbsp;Gurdeep Gogna MS ,&nbsp;Girma Moges Ayele MD ,&nbsp;Miriam Michael MD ,&nbsp;Kashif M. Munir MD","doi":"10.1016/j.aace.2023.10.001","DOIUrl":"10.1016/j.aace.2023.10.001","url":null,"abstract":"<div><h3>Background/Objective</h3><p>Our objective is to highlight the importance of identifying symptoms of steroid-responsive encephalopathy with associated thyroiditis (SREAT), especially in the setting of intermittent cognitive dysfunction, and to inform that SREAT can develop even in patients with a history of partial thyroidectomies.</p></div><div><h3>Case Report</h3><p>We present a case of a 51-year-old woman with a long-standing history of hypothyroidism presenting with acute onset myoclonus, involuntary tremors, fatigue, malaise, and palpitations for two weeks, with intermittent lapses in cognitive function. The patient’s workup is completely within normal limits, including her cognition, except for elevated thyroid stimulating hormone levels and markedly elevated levels of antithyroid peroxidase antibodies, despite the fact that she previously had a partial thyroidectomy.</p></div><div><h3>Discussion</h3><p>SREAT is an autoimmune condition characterized by cognitive dysfunction, elevated thyroid autoantibodies, and therapeutic response to corticosteroids. SREAT is primarily considered a diagnosis of exclusion. A crucial feature is the hallmark of significant improvement in symptoms when glucocorticoids are administered. There is a significant correlation between patients with elevated antithyroid peroxidase antibodies and new-onset SREAT. Although total thyroidectomy has been reported as a definitive treatment of SREAT, response to corticosteroids is the “sine qua non” in diagnosing this condition.</p></div><div><h3>Conclusion</h3><p>Hashimoto's thyroiditis can lead to a rare complication called SREAT, presenting with various neurologic symptoms. Prompt glucocorticoid treatment is vital, and a positive response confirms the diagnosis. Total thyroidectomy may be necessary for definitive SREAT treatment. More research is needed for alternate treatments and an understanding of the pathophysiology of SREAT.</p></div>","PeriodicalId":7051,"journal":{"name":"AACE Clinical Case Reports","volume":"9 6","pages":"Pages 205-208"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2376060523001426/pdfft?md5=04f547e13bc60d2db0af6338f7c6dcb2&pid=1-s2.0-S2376060523001426-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134979274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Atypical Femur Fracture Unmasking Follicular Thyroid Cancer in a 54-year-old Woman","authors":"Jennifer S. Hatfield DO ,&nbsp;Peter N. Bonneau MD ,&nbsp;Mohamed K.M. Shakir MD ,&nbsp;Thanh D. Hoang DO","doi":"10.1016/j.aace.2023.07.005","DOIUrl":"10.1016/j.aace.2023.07.005","url":null,"abstract":"","PeriodicalId":7051,"journal":{"name":"AACE Clinical Case Reports","volume":"9 6","pages":"Pages 213-215"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S237606052300130X/pdfft?md5=94b2870ca3f574d0bb3175bbe41c4e34&pid=1-s2.0-S237606052300130X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44513828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Two Transgender Men Receiving Subdermal Testosterone Pellets for Gender Affirmation","authors":"Sune L. Wolf Pulsiano M3,&nbsp;Jenna L. Sarvaideo DO","doi":"10.1016/j.aace.2023.09.005","DOIUrl":"10.1016/j.aace.2023.09.005","url":null,"abstract":"<div><h3>Background/Objective</h3><p>Testosterone treatment is employed in transgender men to help them affirm their gender. Our objective is to report the cases of 2 transgender men who received subdermal testosterone pellets as the mode of testosterone administration.</p></div><div><h3>Case Report</h3><p>Both patients presented for discussion of testosterone therapy. Patient 1 was a 47-year-old transgender male. He had bilateral mastectomy and total abdominal hysterectomy with bilateral salpingo-oophorectomy (TAH-BSO). Physical exam was significant for obesity. He was on injectable testosterone for 9 years and experienced voice deepening, facial hair growth, temporal hair thinning, and increased skin oiliness, but was interested in a long-acting testosterone formulation. Pellets were well tolerated, but the patient ultimately chose to return to injections. Patient 2 was a 20-year-old transgender male with no history of gender-affirming surgeries. Physical exam was pertinent for a thin, masculinized individual. He started on testosterone gel, but switched to weekly injections, on which he experienced voice deepening, increased skin oiliness and cessation of menses. Due to pain with injections and desire for a long-acting formulation, he elected to try pellets.</p></div><div><h3>Discussion</h3><p>The dose of testosterone pellets used in transgender men are similar to those employed for testosterone replacement in hypogonadal cisgender men.</p></div><div><h3>Conclusion</h3><p>Subdermal testosterone pellets may be suitable as a means of delivering testosterone in transgender men, but the 2 cases reported here do not permit firm conclusions. Given the widespread use of testosterone for gender affirmation in transgender men, a prospective controlled study of subdermal testosterone pellets seems indicated.</p></div>","PeriodicalId":7051,"journal":{"name":"AACE Clinical Case Reports","volume":"9 6","pages":"Pages 201-204"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2376060523001414/pdfft?md5=6d6066483ae23dbb89f479ffc14a2485&pid=1-s2.0-S2376060523001414-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135638494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Middle-aged Woman With Recurrent Intrathyroidal Parathyroid Cyst Treated With Ethanol Sclerotherapy","authors":"Paula Lorena Castellanos Sanchez MD ,&nbsp;Ana Maria Chindris MD ,&nbsp;Ricardo Paz-Fumagalli MD ,&nbsp;Safana Ismail MBBS ,&nbsp;Victor Joseph Bernet MD","doi":"10.1016/j.aace.2023.08.001","DOIUrl":"10.1016/j.aace.2023.08.001","url":null,"abstract":"<div><h3>Background/Objective</h3><p>Parathyroid cysts (PC) are a rare cause of cervical masses, with an ectopic intrathyroidal location being even more rare, with only 9 cases reported in the literature. We present a case of a recurrent intrathyroidal cyst successfully treated with ethanol sclerotherapy.</p></div><div><h3>Case Report</h3><p>A 64-year-old woman presented to our clinic in 2017 with a cervical prominence and recurrent pressure sensation in her left lower neck. She had a history of multiple cyst aspiration drainage procedures for a recurrent intrathyroidal PC. Ultrasound revealed a simple cyst measuring 5.1 cm × 2.1 cm × 1.7 cm encompassing most of the left thyroid lobe. Parathyroid hormone level in the cyst fluid was elevated, but serum calcium and parathyroid hormone levels were within normal range. To prevent additional recurrences, ethanol sclerosis of the cyst was performed. After 6 years of follow-up, the patient remains asymptomatic and without evidence of PC recurrence.</p></div><div><h3>Discussion</h3><p>Although surgical resection of PC can be performed, in the case of an intrathyroidal PC, this would involve loss of functional thyroid tissue and the potential risk of postoperative hypothyroidism. Ethanol sclerosis has been successfully utilized to shrink both thyroid cysts and orthotopically positioned PCs while preserving thyroid tissue. In this case, ethanol sclerosis was used to successfully manage an intrathyroidal PC.</p></div><div><h3>Conclusion</h3><p>Based on the excellent response in this case and reports of efficacy of sclerosis in orthotopically positioned PCs, we conclude that ethanol sclerotherapy seems to be an effective treatment option for recurrent intrathyroidal PCs.</p></div>","PeriodicalId":7051,"journal":{"name":"AACE Clinical Case Reports","volume":"9 6","pages":"Pages 186-188"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2376060523001311/pdfft?md5=fc0053868f09e0b665ad0d82c674b290&pid=1-s2.0-S2376060523001311-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135656882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}